CT1-3 is a potent anticancer agent that induces mitochondrial-mediated apoptosis by modulating the JNK/Bcl-2/Bax/XIAP pathway; it suppresses the epithelial-mesenchymal transition (EMT) potential of human cancer cells (HCCs) by regulating the E-cadherin/Snail axis, thereby inhibiting tumorigenesis; CT1-3 exhibits antitumor activity in mouse models without significant hepatotoxicity or nephrotoxicity.